Skip to main content

Table 1 Activation index (%) by region of interest (ROI) analysis in different conditions of SNI and sham groups

From: Gabapentin reverses central hypersensitivity and suppresses medial prefrontal cortical glucose metabolism in rats with neuropathic pain

ROIs

SNI group (n = 12)

Sham group (n = 10)

Naïve

SNI

GBP

Naïve

Sham

GBP

mPFC i

36.5 ± 2.1

35.2 ± 2.0

* 29.6 ± 1.1

34.6 ± 2.2

35.9 ± 1.3

31.5 ± 1.6

mPFC c

37.9 ± 1.8

35.0 ± 2.0

* 29.7 ± 1.2

33.1 ± 2.2

33.5 ± 1.5

28.6 ± 2.0

ACC i

36.9 ± 1.7

37.4 ± 2.6

* 31.4 ± 1.3

37.3 ± 1.8

37.9 ± 1.5

34.1 ± 2.8

ACC c

34.7 ± 1.4

35.6 ± 2.6

32.3 ± 1.4

34.5 ± 1.8

35.8 ± 1.9

32.2 ± 2.8

RSC i

20.0 ± 1.7

# 14.8 ± 2.4

14.5 ± 2.1

18.9 ± 1.7

15.1 ± 2.3

15.4 ± 2.4

RSC c

20.2 ± 1.6

# 14.8 ± 2.3

13.7 ± 2.2

18.8 ± 1.9

15.0 ± 2.8

15.0 ± 2.8

IC i

1.4 ± 1.5

# 4.8 ± 1.4

3.6 ± 1.8

1.3 ± 2.1

0.3 ± 2.1

1.6 ± 3.1

IC c

1.3 ± 1.4

# 5.1 ± 1.5

3.6 ± 1.6

1.4 ± 2.0

0.5 ± 2.1

1.5 ± 3.0

S1HL i

14.7 ± 1.3

15.7 ± 1.3

15.1 ± 2.0

15.3 ± 1.6

12.3 ± 1.5

13.0 ± 3.1

S1HL c

15.3 ± 1.6

15.7 ± 1.6

15.2 ± 1.1

13.5 ± 2.3

12.5 ± 1.6

13.0 ± 3.0

S1BF i

18.7 ± 0.9

18.0 ± 1.6

** 25.0 ± 1.0

18.5 ± 1.3

18.5 ± 1.1

21.5 ± 2.4

S1BF c

18.6 ± 1.0

18.7 ± 1.5

** 25.7 ± 1.0

18.5 ± 1.3

17.6 ± 0.8

22.6 ± 2.4

S1ULp i

19.4 ± 1.6

19.7 ± 1.5

*** 27.2 ± 1.2

21.8 ± 1.3

22.6 ± 1.8

25.9 ± 2.0

S1ULp c

17.9 ± 1.5

19.3 ± 1.6

** 27.1 ± 1.4

22.3 ± 2.0

21.1 ± 0.9

24.0 ± 2.2

S2

9.8 ± 1.9

10.4 ± 1.7

* 16.4 ± 1.9

11.9 ± 1.4

10.4 ± 1.8

15.2 ± 2.0

S2

10.4 ± 2.2

10.8 ± 1.8

** 20.1 ± 1.4

14.3 ± 1.7

10.8 ± 1.3

13.6 ± 2.1

M1 i

14.1 ± 2.3

15.2 ± 1.5

15.5 ± 0.8

16.2 ± 1.8

15.3 ± 2.0

16.7 ± 3.1

M1 c

13.9 ± 2.9

13.3 ± 1.8

16.1 ± 1.1

14.6 ± 1.7

15.3 ± 2.1

15.2 ± 2.8

CPu i

31.8 ± 1.6

28.6 ± 1.9

28.6 ± 1.3

28.6 ± 1.5

28.9 ± 1.4

28.7 ± 2.2

CPu c

33.7 ± 1.2

28.8 ± 1.9

29.7 ± 1.4

30.4 ± 1.4

28.9 ± 1.5

29.5 ± 2.2

Po i

21.4 ± 1.1

# 26.2 ± 1.6

** 21.0 ± 1.3

22.2 ± 1.2

23.9 ± 1.2

21.8 ± 2.3

Po c

24.5 ± 1.0

27.8 ± 1.7

** 22.3 ± 1.4

23.7 ± 1.2

25.0 ± 1.4

23.3 ± 2.1

VP i

8.4 ± 1.1

## 13.2 ± 1.2

9.5 ± 1.1

11.1 ± 1.3

10.0 ± 1.2

8.2 ± 1.8

VP c

9.3 ± 1.0

12.3 ± 0.9

* 9.2 ± 1.1

10.1 ± 1.3

11.0 ± 1.2

8.5 ± 1.7

AMY i

-9.3 ± 1.2

-11.3 ± 1.3

* -7.9 ± 1.2

-10.9 ± 0.9

-13.0 ± 1.4

-10.4 ± 0.9

AMY c

-5.3 ± 1.2

# -7.0 ± 1.1

-5.8 ± 1.4

-8.1 ± 0.6

-10.0 ± 1.3

-9.3 ± 1.0

Cb vermis

4.7 ± 1.7

## 12.0 ± 1.2

** 6.9 ± 1.2

5.2 ± 1.7

5.6 ± 1.7

7.2 ± 2.0

  1. Post-surgery (SNI) compared to pre-surgery (Naïve) by the one-way repeated measures ANOVA, #P < 0.05, ##P < 0.01. Gabapentin treatment (GBP) compared to post-surgery by the one-way repeated measures ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001. i: ipsilateral; c: contralateral. Data were presented as mean ± SEM. Abbreviations refer to the main text.
Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us